Document:

EX-10.1

[EPICEPT LETTERHEAD]

September 24, 2012

Re: Reset Offer

Dear Security Holder:

We are pleased to offer to you the opportunity to reprice all of the shares of Series A and B
0% Convertible Preferred Stock (collectively, the “Preferred Stock”) and Common Stock
Purchase Warrants (“Warrants”) held by you. Reference is made to those certain Securities
Purchase Agreements (collectively, the “Agreements”), dated February 8, 2012 and March 28,
2012, by and between EpiCept Corporation (the “Company”) and you, pursuant to which the
Preferred Stock and Warrants were issued. The shares of Preferred Stock, Warrants and exercise of
the shares underlying the Warrants (“Warrant Shares”) have been registered for sale
pursuant to a registration statement on Form S-1 (File No. 333-160571) (the “Registration
Statement”). The Company believes, in good faith, that such effectiveness will continue
uninterrupted for the foreseeable future.

In consideration for exercising in full the Warrants (collectively 8,132,353 Warrant Shares)
(the “Warrant Exercise”), the Company hereby offers you a reduced exercise price of $0.10
and an irrevocable and permanent reduced Conversion Price (as defined in the Agreement) on all of
the Preferred Stock (1,301 shares) of $0.08, subject to adjustment therein. Expressly subject to
the paragraph immediately following this paragraph below, you may accept this offer by signing this
letter below, with such acceptance constituting your exercise in full of the Warrants for an
aggregate exercise price of $813,235.30 (the “Warrants Exercise Price”). Upon receipt of
the Warrants Exercise Price, the Company shall cause the Conversion Price of all of the shares of
Preferred Stock held by you to be reduced, without any further action by you or the Company, to
$0.08, subject to adjustment therein. As part of accepting this offer, you are not required to
convert any of your Preferred Stock. Additionally, in order to facilitate the exercise of the
Warrants, the Company agrees to hereby increase the Beneficial Ownership Limitation in Section 2(e)
of the Warrants to 9.9%.

In implementation of the foregoing, the parties hereto agree that the full Warrant Exercise
would result in you or any of your affiliates owning in excess of the Beneficial Ownership
Limiation, as amended above. Accordingly, you shall initially receive, and the Company shall
initially issue, 7,800,000 shares of Common Stock such that your beneficial ownership in the
Company’s common stock is less than the Beneficial Ownership Limitation. After such initial
issuance, within 2 business days written notice from you that your beneficial ownership of the
common stock of the Company is such that the the balance of the 332,353 shares issuable in the
Warrant Exercise (“Remaining Balance”) may be issued without exceeding the Beneficial
Ownership Limitation, the Company shall issue such Remaining Balance to you. The provisions of
this paragraph shall be construed and implemented in a manner otherwise than in strict conformity
with the terms of this Section 2(e) of the Warrants to correct this paragraph (or any portion
hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation
therein contained or to make changes or supplements necessary or desirable to properly give effect
to such limitation.

On or before 1:00 a.m. Eastern Time on the business day immediately following the date hereof,
the Company shall issue a press release disclosing the material terms hereunder, and on or before
8:30 a.m. Eastern Time on the business day immediately following the date the Company receives the
Warrants Exercise Price, the Company shall have filed a prospectus supplement to the registration
statement registering the exercise of the Warrants and disclosing the terms of this offer and an
amendment to the Certificates of Designation reflecting the new Conversion Price. Copies of such
supplement and certificates of amendment are attached to this letter. The Company represents,
warrants and covenants that, upon acceptance of this offer, the shares underlying the Preferred
Stock (when converted) and Warrants shall be issued free of any legends or restrictions on resale
by you and all of the Warrant Shares shall be delivered electronically through the Depository Trust
Company within 2 business days of the date the Company receives the Warrants Exercise Price (or,
with respect to shares in that would otherwise be in excess of the Beneficial Ownership Limitation,
within 2 business days of the date the Company is notified by you that your ownership is less than
the Beneficial Ownership Limitation). The terms of the Warrants, including but not limited to the
obligations to deliver the Warrant Shares, shall otherwise remain in effect as if the acceptance of
this offer were a formal Notice of Exercise (including but not limited to any liquidated damages
and compensation in the event of late delivery of the Warrant Shares).

To accept this offer, you must counter execute this letter agreement and return the fully
executed agreement to the Company at (914) 606-3501, attn.: Robert W. Cook, Interim President &
CEO.

Please do not hesitate to call me if you have any questions.

Sincerely yours,

EPICEPT CORPORATION

By:       

Name:

Title:

Wire Instructions:

Accepted and Agreed to:

By:       

Name:

Title:

DTC Instructions:EX-10.2

September 24, 2012

STRICTLY CONFIDENTIAL

EpiCept Corporation

777 Old Saw Mill River Road

Tarrytown, NY 10591

Attn: Robert W. Cook

Senior Vice President & Chief Financial Officer

Dear Mr. Cook:

This letter (the “Agreement”) constitutes the agreement between EpiCept Corporation
(the “Company”) and Dawson James, Inc. (“Dawson”) that Dawson shall serve as the
exclusive placement agent (the “Services”) for the Company, on a reasonable best efforts
basis, in connection with the exercise of certain Common Stock Purchase Warrants (the
“Warrants”) of the Company (the “Warrant Exercise”) to purchase 8,132,353 shares of
common stock (“Warrant Shares”) of the Company thereof for an aggregate purchase price of
$813,235.30 (“Aggregate Gross Proceeds”). The Warrants were issued pursuant to those
certain Securities Purchase Agreements dated February 8, 2012 and March 28, 2012. The terms of the
Warrant Exercise shall be mutually agreed upon by the Company and the investors and nothing herein
implies that Dawson would have the power or authority to bind the Company or an obligation for the
Company to issue any Warrants or complete the Warrant Exercise. The Company expressly acknowledges
and agrees that the execution of this Agreement does not constitute a commitment by Dawson to
purchase the Warrants or exercise the Warrants and does not ensure the successful exercise of the
Warrants or any portion thereof or the success of Dawson with respect to securing any other
financing on behalf of the Company. Annex A will apply to the provisions set forth herein.

A. Fees and Expenses. In connection with the Services described above, the Company
shall pay to Dawson the following compensation:

1. Placement Agent’s Fee. The Company shall pay to Dawson a cash placement fee
(the “Placement Agent’s Fee”) equal to 7% of the Aggregate Gross Proceeds. The
Placement Agent’s Closing Fee shall be paid promptly upon payment of the Aggregate Gross
Proceeds to the Company (the “Closing”).

2. Expenses. In addition to any fees payable to Dawson hereunder, the Company
hereby agrees to pay Dawson a non-accountable expense allowance equal to the lesser of (a)
$8,000 and (b) $1% of the Aggregate Gross Proceeds (provided, however, that such expense cap
in no way limits or impairs the indemnification and contribution provisions of this
Agreement).

B. Term and Termination of Engagement. The term (the “Term”) of Dawson’s
engagement will begin on the date hereof and end upon the successful completion of the Warrant
Exercise. Notwithstanding anything to the contrary contained herein, the provisions concerning
confidentiality, indemnification, contribution and the Company’s obligations to pay fees actually
earned and payable and to reimburse expenses actually incurred and reimbursable pursuant to Section
A hereof, will survive any expiration or termination of this Agreement.

C. Use of Information. The Company will furnish Dawson such written information as
Dawson reasonably requests in connection with the performance of its services hereunder. The
Company understands, acknowledges and agrees that, in performing its services hereunder, Dawson
will use and rely entirely upon such information as well as publicly available information
regarding the Company and other potential parties to an Warrant Exercise and that Dawson does not
assume responsibility for independent verification of the accuracy or completeness of any
information, whether publicly available or otherwise furnished to it, concerning the Company or
otherwise relevant to an Warrant Exercise, including, without limitation, any financial
information, forecasts or projections considered by Dawson in connection with the provision of its
services.

D. Publicity. In the event of the consummation or public announcement of any Warrant
Exercise, Dawson shall have the right to disclose its participation in such Warrant Exercise,
including, without limitation, the placement at its cost of “tombstone” advertisements in financial
and other newspapers and journals.

E. Securities Matters. The Company shall be responsible for any and all compliance
with the securities laws applicable to it, including Regulation D and the Securities Act of 1933,
as amended (the “Securities Act”), and Rule 506 promulgated thereunder, and unless
otherwise agreed in writing, all state securities (“blue sky”) laws. Dawson agrees to
cooperate with counsel to the Company in that regard.

F. Representations and Warranties.

1. Dawson shall be entitled to rely on the representations, warranties, agreements, conditions
and covenants of the Company contained in any agreements entered into with the Investors in an
Warrant Exercise, and such representations, warranties, agreements, conditions and covenants are
hereby incorporated by reference into this Agreement as though fully stated herein.

2. The Company acknowledges that the Warrant Exercise of convertible Securities may create
significant risks, including the risk that the Company may have insufficient cash resources and/or
registered shares to timely meet its payment and conversion obligations. The Company further
acknowledges that, depending on the number and price of new shares issued, such transaction may
result in substantial dilution which could adversely affect the market price of the Company’s
shares.

3. The Company has the requisite corporate power and authority to enter into and to consummate
the transactions contemplated by this Agreement and otherwise to carry out its obligations
hereunder. The execution and delivery of this Agreement by the Company and the consummation by it
of the transactions contemplated hereby have been duly authorized by all necessary action on the
part of the Company and no further action is required by the Company, its board of directors or its
stockholders in connection herewith. This Agreement has been (or upon delivery will have been)
duly executed by the Company and, when delivered in accordance with the terms hereof and thereof,
will constitute the valid and binding obligation of the Company enforceable against the Company in
accordance with its terms except (i) as limited by applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application affecting enforcement of
creditors’ rights generally and (ii) as limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies.

4. The execution, delivery and performance of this Agreement by the Company, the proposed
issuance and sale of the Securities and the consummation by the Company of the other transactions
contemplated hereby do not and will not (i) conflict with or violate any provision of the Company’s
or any Subsidiary of the Company’s (“Subsidiaries”) certificate or articles of
incorporation, bylaws or other organizational or charter documents, or (ii) conflict with, or
constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any lien upon any of the properties or assets of the Company or
any Subsidiary, or give to others any rights of termination, amendment, acceleration or
cancellation (with or without notice, lapse of time or both) of, any agreement, credit facility,
debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other
understanding to which the Company or any Subsidiary is a party or by which any property or asset
of the Company or any Subsidiary is bound or affected, or (iii) conflict with or result in a
violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of
any court or governmental authority to which the Company or a Subsidiary is subject (including
federal and state securities laws and regulations), or by which any property or asset of the
Company or a Subsidiary is bound or affected.

5. The Company is not required to obtain any consent, waiver, authorization or order of, give
any notice to, or make any filing or registration with, any court or other federal, state, local or
other governmental authority or other “Person” (defined as an individual or corporation,
partnership, trust, incorporated or unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or subdivision thereof) or other entity of
any kind, including, without limitation, any trading market) in connection with the execution,
delivery and performance by the Company of this Agreement, other than such filings as are required
to be made under applicable Federal and state securities laws.

6. Except as required hereunder, no brokerage or finder’s fees or commissions are or will be
payable by the Company to any broker, financial advisor or consultant, finder, placement agent,
investment banker, bank or other Person with respect to the transactions contemplated by this
Agreement.

7. The Company has not, and to its knowledge no one acting on its behalf has, (i) taken,
directly or indirectly, any action designed to cause or to result in the stabilization or
manipulation of the price of any security of the Company to facilitate the sale or resale of any of
the Securities, (ii) sold, bid for, purchased, or, paid any compensation for soliciting purchases
of, any of the Securities (other than for the Placement Agent’s placement of the Securities), or
(iii) paid or agreed to pay to any person any compensation for soliciting another to purchase any
other securities of the Company.

8. There are no affiliations with any FINRA member firm among the Company’s officers,
directors or, to the knowledge of the Company, any five percent (5%) or greater stockholder of the
Company.

G. Indemnity.

1. In connection with the Company’s engagement of Dawson as placement agent, the Company
hereby agrees to indemnify and hold harmless Dawson and its affiliates, and the respective
controlling persons, directors, officers, shareholders, agents and employees of any of the
foregoing (collectively the “Indemnified Persons”), from and against any and all claims,
actions, suits, proceedings (including those of shareholders), damages, liabilities and expenses
incurred by any of them (including the reasonable fees and expenses of counsel), as incurred,
(collectively a “Claim”), that are (A) related to or arise out of (i) any actions taken or
omitted to be taken (including any untrue statements made or any statements omitted to be made) by
the Company, or (ii) any actions taken or omitted to be taken by any Indemnified Person in
connection with the Company’s engagement of Dawson, or (B) otherwise relate to or arise out of
Dawson’s activities on the Company’s behalf under Dawson’s engagement, and the Company shall
reimburse any Indemnified Person for all expenses (including the reasonable fees and expenses of
counsel) as incurred by such Indemnified Person in connection with investigating, preparing or
defending any such claim, action, suit or proceeding, whether or not in connection with pending or
threatened litigation in which any Indemnified Person is a party. The Company will not, however,
be responsible for any Claim that is finally judicially determined to have resulted from the gross
negligence or willful misconduct of any person seeking indemnification for such Claim. The Company
further agrees that no Indemnified Person shall have any liability to the Company for or in
connection with the Company’s engagement of Dawson except for any Claim incurred by the Company as
a result of such Indemnified Person’s gross negligence or willful misconduct.

2. The Company further agrees that it will not, without the prior written consent of Dawson,
settle, compromise or consent to the entry of any judgment in any pending or threatened Claim in
respect of which indemnification may be sought hereunder (whether or not any Indemnified Person is
an actual or potential party to such Claim), unless such settlement, compromise or consent includes
an unconditional, irrevocable release of each Indemnified Person from any and all liability arising
out of such Claim.

3. Promptly upon receipt by an Indemnified Person of notice of any complaint or the assertion
or institution of any Claim with respect to which indemnification is being sought hereunder, such
Indemnified Person shall notify the Company in writing of such complaint or of such assertion or
institution but failure to so notify the Company shall not relieve the Company from any obligation
it may have hereunder, except and only to the extent such failure results in the forfeiture by the
Company of substantial rights and defenses. If the Company so elects or is requested by such
Indemnified Person, the Company will assume the defense of such Claim, including the employment of
counsel reasonably satisfactory to such Indemnified Person and the payment of the fees and expenses
of such counsel. In the event, however, that legal counsel to such Indemnified Person reasonably
determines that having common counsel would present such counsel with a conflict of interest or if
the defendant in, or target of, any such Claim, includes an Indemnified Person and the Company, and
legal counsel to such Indemnified Person reasonably concludes that there may be legal defenses
available to it or other Indemnified Persons different from or in addition to those available to
the Company, then such Indemnified Person may employ its own separate counsel to represent or
defend him, her or it in any such Claim and the Company shall pay the reasonable fees and expenses
of such counsel. Notwithstanding anything herein to the contrary, if the Company fails timely or
diligently to defend, contest, or otherwise protect against any Claim, the relevant Indemnified
Party shall have the right, but not the obligation, to defend, contest, compromise, settle, assert
crossclaims, or counterclaims or otherwise protect against the same, and shall be fully indemnified
by the Company therefor, including without limitation, for the reasonable fees and expenses of its
counsel and all amounts paid as a result of such Claim or the compromise or settlement thereof. In
addition, with respect to any Claim in which the Company assumes the defense, the Indemnified
Person shall have the right to participate in such Claim and to retain his, her or its own counsel
therefor at his, her or its own expense.

4. The Company agrees that if any indemnity sought by an Indemnified Person hereunder is held
by a court to be unavailable for any reason then (whether or not Dawson is the Indemnified Person),
the Company and Dawson shall contribute to the Claim for which such indemnity is held unavailable
in such proportion as is appropriate to reflect the relative benefits to the Company, on the one
hand, and Dawson on the other, in connection with Dawson’s engagement referred to above, subject to
the limitation that in no event shall the amount of Dawson’s contribution to such Claim exceed the
amount of fees actually received by Dawson from the Company pursuant to Dawson’s engagement. The
Company hereby agrees that the relative benefits to the Company, on the one hand, and Dawson on the
other, with respect to Dawson’s engagement shall be deemed to be in the same proportion as (a) the
total value paid or proposed to be paid or received by the Company or its stockholders as the case
may be, pursuant to the Warrant Exercise (whether or not consummated) for which Dawson is engaged
to render services bears to (b) the fee paid or proposed to be paid to Dawson in connection with
such engagement.

5. The Company’s indemnity, reimbursement and contribution obligations under this Agreement
(a) shall be in addition to, and shall in no way limit or otherwise adversely affect any rights
that any Indemnified Party may have at law or at equity and (b) shall be effective whether or not
the Company is at fault in any way.

H. Limitation of Engagement to the Company. The Company acknowledges that Dawson has
been retained only by the Company, that Dawson is providing services hereunder as an independent
contractor (and not in any fiduciary or agency capacity) and that the Company’s engagement of
Dawson is not deemed to be on behalf of, and is not intended to confer rights upon, any
shareholder, owner or partner of the Company or any other person not a party hereto as against
Dawson or any of its affiliates, or any of its or their respective officers, directors, controlling
persons (within the meaning of Section 15 of the Securities Act or Section 20 of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”)), employees or agents. Unless otherwise
expressly agreed in writing by Dawson, no one other than the Company is authorized to rely upon
this Agreement or any other statements or conduct of Dawson, and no one other than the Company is
intended to be a beneficiary of this Agreement. The Company acknowledges that any recommendation
or advice, written or oral, given by Dawson to the Company in connection with Dawson’s engagement
is intended solely for the benefit and use of the Company’s management and directors in considering
a possible Warrant Exercise, and any such recommendation or advice is not on behalf of, and shall
not confer any rights or remedies upon, any other person or be used or relied upon for any other
purpose. Dawson shall not have the authority to make any commitment binding on the Company. The
Company, in its sole discretion, shall have the right to reject any investor introduced to it by
Dawson. The Company agrees that it will perform and comply with the covenants and other
obligations set forth in the purchase agreement and related transaction documents between the
Company and the investors in the Warrant Exercise, and that Dawson will be entitled to rely on the
representations, warranties, agreements and covenants of the Company contained in such purchase
agreement and related transaction documents as if such representations, warranties, agreements and
covenants were made directly to Dawson by the Company.

I. Limitation of Dawson’s Liability to the Company. Dawson and the Company further
agree that neither Dawson nor any of its affiliates or any of its their respective officers,
directors, controlling persons (within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act), employees or agents shall have any liability to the Company, its security
holders or creditors, or any person asserting claims on behalf of or in the right of the Company
(whether direct or indirect, in contract, tort, for an act of negligence or otherwise) for any
losses, fees, damages, liabilities, costs, expenses or equitable relief arising out of or relating
to this Agreement or the Services rendered hereunder, except for losses, fees, damages,
liabilities, costs or expenses that arise out of or are based on any action of or failure to act by
Dawson and that are finally judicially determined to have resulted solely from the gross negligence
or willful misconduct of Dawson.

J. Governing Law. This Agreement shall be governed by and construed in accordance
with the laws of the State of New York applicable to agreements made and to be fully performed
therein. Any disputes that arise under this Agreement, even after the termination of this
Agreement, will be heard only in the state or federal courts located in the City of New York, State
of New York. The parties hereto expressly agree to submit themselves to the jurisdiction of the
foregoing courts in the City of New York, State of New York. The parties hereto expressly waive any
rights they may have to contest the jurisdiction, venue or authority of any court sitting in the
City and State of New York. In the event of the bringing of any action, or suit by a party hereto
against the other party hereto, arising out of or relating to this Agreement, the party in whose
favor the final judgment or award shall be entered shall be entitled to have and recover from the
other party the costs and expenses incurred in connection therewith, including its reasonable
attorneys’ fees. Any rights to trial by jury with respect to any such action, proceeding or suit
are hereby waived by Dawson and the Company.

K. Notices. Any and all notices or other communications or deliveries required or
permitted to be provided hereunder shall be in writing and shall be deemed given and effective on
the earliest of (a) the date of transmission, if such notice or communication is delivered via
facsimile at the facsimile number specified on the signature pages attached hereto prior to 6:30
p.m. (New York City time) on a business day, (b) the next business day after the date of
transmission, if such notice or communication is delivered via facsimile at the facsimile number on
the signature pages attached hereto on a day that is not a business day or later than 6:30 p.m.
(New York City time) on any business day, (c) the business day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service, or (d) upon actual receipt by the
party to whom such notice is required to be given. The address for such notices and communications
shall be as set forth on the signature pages hereto.

L. Miscellaneous. This Agreement shall not be modified or amended except in writing
signed by Dawson and the Company. This Agreement shall be binding upon and inure to the benefit of
both Dawson and the Company and their respective assigns, successors, and legal representatives.
This Agreement constitutes the entire agreement of Dawson and the Company, and supersedes any prior
agreements, with respect to the subject matter hereof. If any provision of this Agreement is
determined to be invalid or unenforceable in any respect, such determination will not affect such
provision in any other respect, and the remainder of the Agreement shall remain in full force and
effect. This Agreement may be executed in counterparts (including facsimile counterparts), each of
which shall be deemed an original but all of which together shall constitute one and the same
instrument.

****************

1

In acknowledgment that the foregoing correctly sets forth the understanding reached by Dawson
and the Company, please sign in the space provided below, whereupon this letter shall constitute a
binding Agreement as of the date indicated above.

Very truly yours,

DAWSON JAMES SECURITIES, INC.

By:       

Name:

Title:

Address for notice:

925 South Federal Highway, Suite 600

Boca Raton, FL 33432

Fax (561) 931-5757

Attention: Head of Investment Banking

Accepted and Agreed:

EPICEPT CORPORATION

By       

Name:

Title:

2

Annex A

Additional Provisions With Respect to the Warrant Exercise

SECTION 2. REGISTRATION STATEMENT.

The Company represents and warrants to, and agrees with, the Placement Agent that:

(A) The Company has filed with the Securities and Exchange Commission (the “Commission”) a
registration statement on Form S-1 (Registration File No. 333-160571) under the Securities Act of
1933, as amended (the “Securities Act”), which became effective on May 2, 2012 for the
registration under the Securities Act of the Warrant Shares. At the time of such filing, the
Company met the requirements of Form S-1 under the Securities Act. The Company will file with the
Commission pursuant to Rule 424(b) under the Securities Act, and the rules and regulations (the
“Rules and Regulations”) of the Commission promulgated thereunder, a supplement to the form
of prospectus included in such registration statement relating to the placement of the Warrant
Shares and the plan of distribution thereof and has advised the Placement Agent of all further
information (financial and other) with respect to the Company required to be set forth therein.
Such registration statement, including the exhibits thereto, as amended at the date of this
Agreement, is hereinafter called the “Registration Statement”; such prospectus in the form
in which it appears in the Registration Statement is hereinafter called the “Base
Prospectus”; and the supplemented form of prospectus, in the form in which it will be filed
with the Commission pursuant to Rule 424(b) (including the Base Prospectus as so supplemented) is
hereinafter called the “Prospectus Supplement.” No stop order suspending the effectiveness
of the Registration Statement or the use of the Base Prospectus or the Prospectus Supplement has
been issued, and no proceeding for any such purpose is pending or has been initiated or, to the
Company’s knowledge, is threatened by the Commission. For purposes of this Agreement, “free writing
prospectus” has the meaning set forth in Rule 405 under the Securities Act and the “Time of
Sale Prospectus” means the preliminary prospectus, if any, together with the free writing
prospectuses, if any, used in connection with the Warrant Exercise, including any documents
incorporated by reference therein.

(B) The Registration Statement (and any further documents to be filed with the Commission)
contains all exhibits and schedules as required by the Securities Act. Each of the Registration
Statement and any post-effective amendment thereto, at the time it became effective, complied in
all material respects with the Securities Act and the Exchange Act and the applicable Rules and
Regulations and did not and, as amended or supplemented, if applicable, will not, contain any
untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading. The Base Prospectus, the Time of Sale
Prospectus, if any, and the Prospectus Supplement, each as of its respective date, comply in all
material respects with the Securities Act and the Exchange Act and the applicable Rules and
Regulations. Each of the Base Prospectus, the Time of Sale Prospectus, if any, and the Prospectus
Supplement, as amended or supplemented, did not and will not contain as of the date thereof any
untrue statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading. No
post-effective amendment to the Registration Statement reflecting any facts or events arising after
the date thereof which represent, individually or in the aggregate, a fundamental change in the
information set forth therein is required to be filed with the Commission. There are no documents
required to be filed with the Commission in connection with the transaction contemplated hereby
that (x) have not been filed as required pursuant to the Securities Act or (y) will not be filed
within the requisite time period. There are no contracts or other documents required to be
described in the Base Prospectus, the Time of Sale Prospectus, if any, or Prospectus Supplement, or
to be filed as exhibits or schedules to the Registration Statement, which have not been described
or filed as required.

3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00208-of-00352.parquet"}]]